Amedica to distribute BioDfence DryFlex and Dynamic Bone allograft products

Amedica Corporation, a spinal and reconstructive implant and instrument manufacturer announced today that it will begin distribution of Dynamic Bone, a unique expandable allograft bone provided by Dynamic Surgical Solutions and BioDfence™ DryFlex, an easy to handle, flexible amniotic membrane manufactured by BioDlogics.  These new allograft products provide surgeons with innovative solutions for their patients and expand the Origin® Orthobiologics line of products.

Dynamic Bone is customized, compressed, demineralized cancellous bone that expands like a sponge upon hydration. As an osteoconductive material, Dynamic Bone is ideally suited for spinal fusion procedures, and can be hydrated with osteoinductive liquids such as bone marrow aspirate, bone morphogenic proteins, or other viable tissue matrix products such as BioDfactor™, which is already offered through Amedica.  What makes Dynamic Bone unique is that after placement within the vertebral body it continues to expand, filling any open cavity for a custom press-fit which will help match each patient's anatomy, and may ultimately improve overall fusion rates.

BioDfence DryFlex is a resorbable adhesion barrier derived from amniotic membrane procured from live, healthy donors during childbirth.  It can be used as a physical barrier between the dura and surrounding soft tissue to reduce the potential for post-operative complications due to scar tissue.  The DryFlex strength and flexibility make it ideally suited for MIS procedures.

"Both Dynamic Bone and BioDfence DryFlex provide some of the most advanced biologic technologies available today, and address surgeons' need to improve spinal outcomes," stated Eric Olson, President and CEO of Amedica.  "By adding these two products to our best-in-class orthobiologics portfolio, we expect to drive enhanced revenue growth and company value creation.  Amedica has a strong track record of successfully launching new biologic products and we expect to realize the benefits of these products in both top-line growth and shareholder value over the long-term.  However, the bottom line is that we believe this will help the company reach our ultimate goal of assisting our surgeon customers in improving patient outcomes in an innovative, cost-effective manner," Olson concluded.


Amedica Corporation


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Partial bone marrow transplant can dramatically improve survival of mice with cystic fibrosis